Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.

Schimmer AD, Estey EH, Borthakur G, Carter BZ, Schiller GJ, Tallman MS, Altman JK, Karp JE, Kassis J, Hedley DW, Brandwein J, Xu W, Mak DH, LaCasse E, Jacob C, Morris SJ, Jolivet J, Andreeff M.

J Clin Oncol. 2009 Oct 1;27(28):4741-6. doi: 10.1200/JCO.2009.21.8172. Epub 2009 Aug 3.

2.

Addition of AEG35156 XIAP antisense oligonucleotide in reinduction chemotherapy does not improve remission rates in patients with primary refractory acute myeloid leukemia in a randomized phase II study.

Schimmer AD, Herr W, Hänel M, Borthakur G, Frankel A, Horst HA, Martin S, Kassis J, Desjardins P, Seiter K, Fiedler W, Noppeney R, Giagounidis A, Jacob C, Jolivet J, Tallman MS, Koschmieder S.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):433-8. doi: 10.1016/j.clml.2011.03.033. Epub 2011 May 5.

PMID:
21729686
3.

XIAP antisense oligonucleotide (AEG35156) achieves target knockdown and induces apoptosis preferentially in CD34+38- cells in a phase 1/2 study of patients with relapsed/refractory AML.

Carter BZ, Mak DH, Morris SJ, Borthakur G, Estey E, Byrd AL, Konopleva M, Kantarjian H, Andreeff M.

Apoptosis. 2011 Jan;16(1):67-74. doi: 10.1007/s10495-010-0545-1.

4.

Preclinical characterization of AEG35156/GEM 640, a second-generation antisense oligonucleotide targeting X-linked inhibitor of apoptosis.

LaCasse EC, Cherton-Horvat GG, Hewitt KE, Jerome LJ, Morris SJ, Kandimalla ER, Yu D, Wang H, Wang W, Zhang R, Agrawal S, Gillard JW, Durkin JP.

Clin Cancer Res. 2006 Sep 1;12(17):5231-41.

5.

A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: a report from the Children's Oncology Group.

Horton TM, Perentesis JP, Gamis AS, Alonzo TA, Gerbing RB, Ballard J, Adlard K, Howard DS, Smith FO, Jenkins G, Kelder A, Schuurhuis GJ, Moscow JA.

Pediatr Blood Cancer. 2014 Oct;61(10):1754-60. doi: 10.1002/pbc.25117. Epub 2014 Jun 29.

6.

High-dose cytarabine, idarubicin, and granulocyte colony-stimulating factor remission induction therapy for previously untreated de novo and secondary adult acute myeloid leukemia.

Baer MR, Christiansen NP, Frankel SR, Brunetto VL, Mrózek K, Bloomfield CD, Herzig GP.

Semin Oncol. 1993 Dec;20(6 Suppl 8):6-12.

PMID:
7507264
7.

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML).

Erba HP, Sayar H, Juckett M, Lahn M, Andre V, Callies S, Schmidt S, Kadam S, Brandt JT, Van Bockstaele D, Andreeff M.

Invest New Drugs. 2013 Aug;31(4):1023-34. doi: 10.1007/s10637-013-9935-x. Epub 2013 Feb 10.

8.

Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.

Dinndorf PA, Avramis VI, Wiersma S, Krailo MD, Liu-Mares W, Seibel NL, Sato JK, Mosher RB, Kelleher JF, Reaman GH.

J Clin Oncol. 1997 Aug;15(8):2780-5.

PMID:
9256119
10.

A single, high dose of idarubicin combined with cytarabine as induction therapy for adult patients with recurrent or refractory acute lymphoblastic leukemia.

Weiss MA, Aliff TB, Tallman MS, Frankel SR, Kalaycio ME, Maslak PG, Jurcic JG, Scheinberg DA, Roma TE.

Cancer. 2002 Aug 1;95(3):581-7.

11.
12.

Pilot study of Mylotarg, idarubicin and cytarabine combination regimen in patients with primary resistant or relapsed acute myeloid leukemia.

Alvarado Y, Tsimberidou A, Kantarjian H, Cortes J, Garcia-Manero G, Faderl S, Thomas D, Estey E, Giles FJ.

Cancer Chemother Pharmacol. 2003 Jan;51(1):87-90. Epub 2002 Nov 13.

PMID:
12497211
14.

All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.

Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, Reman O, Dombret H, Dhedin N, Michallet M, Fière D, Archimbaud E.

Hematol J. 2002;3(1):49-55.

PMID:
11960396
16.

Phase 2 randomized study of p53 antisense oligonucleotide (cenersen) plus idarubicin with or without cytarabine in refractory and relapsed acute myeloid leukemia.

Cortes J, Kantarjian H, Ball ED, Dipersio J, Kolitz JE, Fernandez HF, Goodman M, Borthakur G, Baer MR, Wetzler M.

Cancer. 2012 Jan 15;118(2):418-27. doi: 10.1002/cncr.26292. Epub 2011 Jun 29.

17.

A new combination of carboplatin, high-dose cytarabine and cross-over mitoxantrone or idarubicin for refractory and relapsed acute myeloid leukemia.

Bassan R, Lerede T, Buelli M, Borleri G, Bellavita P, Rambaldi A, Barbui T.

Haematologica. 1998 May;83(5):422-7.

18.

Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer.

Dean E, Jodrell D, Connolly K, Danson S, Jolivet J, Durkin J, Morris S, Jowle D, Ward T, Cummings J, Dickinson G, Aarons L, Lacasse E, Robson L, Dive C, Ranson M.

J Clin Oncol. 2009 Apr 1;27(10):1660-6. doi: 10.1200/JCO.2008.19.5677. Epub 2009 Feb 23.

PMID:
19237630
19.

A phase I study of idarubicin dose escalation with amisfostine and high-dose cytarabine in patients with relapsed acute myelogenous leukemia and myelodysplastic syndromes.

Garcia-Manero G, Faderl S, Giles F, Thomas D, Cortes J, O'Brien S, Davis J, Kantarjian HM, Estey E.

Haematologica. 2002 Aug;87(8):804-7.

20.

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.

Hofmann WK, Heil G, Zander C, Wiebe S, Ottmann OG, Bergmann L, Hoeffken K, Fischer JT, Knuth A, Kolbe K, Schmoll HJ, Langer W, Westerhausen M, Koelbel CB, Hoelzer D, Ganser A.

Ann Hematol. 2004 Aug;83(8):498-503. Epub 2004 May 20.

PMID:
15156346

Supplemental Content

Support Center